Heart Failure: Clinical Breakdown: Pathophysiology, Ejection Fraction Classifications, Etiology, Neurohormonal Activation, and Therapeutic Management
A clinical reference on heart failure as a syndrome of impaired ventricular filling or ejection, with the HFrEF, HFmrEF and HFpEF classification, neurohormonal compensation through the sympathetic system and RAAS, and guideline-directed medical therapy.
Submitted research brief - Submitted to OwieClear; written with an AI assistant - November 2026
Read this first. This document was written outside OwieClear and has not been reviewed by a clinician. We publish it so you can read the source for yourself. It is educational and is not medical advice. Where our own pages disagree with it, follow our pages, which cite their sources, and ask a healthcare professional about anything that affects your care.
What we found that needs correcting
- This brief is accurate and well organised, and its central choice is the right one: explaining heart failure through neurohormonal activation rather than as a simple pump problem. The classification table and the GDMT list are both current. The notes below add what a reference like this needs alongside the mechanism.
- One typographical point worth fixing: the core principle paragraph abbreviates left ventricular ejection fraction as LEF, while the table correctly uses LVEF.
- The neurohormonal section explains compensation but stops before the payoff. Each of the four recommended drug classes blocks one of these pathways: ACE inhibitors, ARBs and ARNIs block the RAAS, beta blockers block sympathetic drive, mineralocorticoid receptor antagonists block aldosterone, and the ARNI additionally amplifies the natriuretic peptide system by inhibiting its breakdown. Stating that connection explicitly is what makes the pathophysiology clinically useful.
- The natriuretic peptide system is missing from the compensation discussion, and it is the body's own opposition to the RAAS as well as the basis of the BNP test. Its absence also leaves the sacubitril half of the ARNI unexplained.
- Reverse remodelling deserves a mention. Blocking neurohormonal activation can reduce ventricular size and raise ejection fraction over months, and in some patients ejection fraction returns to normal. This group, now described as heart failure with improved ejection fraction, continues treatment, because withdrawal frequently causes relapse. Patients commonly assume the opposite.
- The management section lists the four classes but not how they are used. They are started at low doses and titrated over weeks, and current practice favours starting all four early at low doses rather than maximising one before adding the next. A low dose of all four is better than a full dose of one, and registry data consistently show patients on incomplete therapy.
- Two practical points belong with that list. Only carvedilol, bisoprolol and metoprolol succinate have proven benefit in heart failure, and other beta blockers are not interchangeable. And switching from an ACE inhibitor to an ARNI requires a 36-hour washout because of angioedema risk.
- Diuretics are mentioned under lifestyle and fluid monitoring but not given their place. They are the mainstay of congestion relief and have not been shown to prolong life, which is the distinction that determines what can be adjusted and what should be protected when blood pressure limits treatment.
- The diagnostic workup is absent. Natriuretic peptides are used principally to rule heart failure out in a breathless patient, echocardiography establishes ejection fraction, structure and valve function, and a completely normal ECG makes HFrEF unlikely. Levels are lower in obesity and higher with age, atrial fibrillation and kidney impairment, which matters for interpretation.
- Two additions to the etiology list. Tachycardia-induced cardiomyopathy from a persistently fast rhythm, usually poorly rate-controlled atrial fibrillation, is reversible when the rate is controlled. And cardiac amyloidosis is considerably more common than previously recognised, particularly in older patients with HFpEF and thick walls, and now has specific treatment.
- Finally, devices and iron. An ICD is considered when ejection fraction remains at or below 35 percent after at least three months of optimised therapy, and cardiac resynchronisation benefits patients with a wide QRS, particularly left bundle branch block. Iron deficiency is common, worsens symptoms independently of anaemia, and responds to intravenous iron.
- Everything else in the brief is accurate: heart failure as a syndrome of structural or functional impairment of ventricular filling or ejection, with dyspnea, fatigue and fluid retention as hallmark features; the LVEF categories as tabulated; coronary artery disease, hypertension, valvular disease, cardiomyopathies and diabetes as leading causes; sympathetic and RAAS activation maintaining perfusion initially then driving adverse remodelling, vasoconstriction and fluid retention; exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea, pitting oedema, raised JVP and fatigue as the clinical presentation; and sodium restriction and fluid monitoring alongside guideline-directed therapy.
Download the PDF
Our reviewed pages on this
All source documents